There are 2867 resources available
206P - HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications
Presenter: Paolo Tarantino
Session: Poster session 02
208P - Automated prognosis marker assessment in 2’004 breast cancers using an artificial intelligence-based framework for BLEACH&STAIN mfIHC
Presenter: Tim Mandelkow
Session: Poster session 02
209P - Efficacy and feasibility of long acting every three months goserelin for premenopausal breast cancer patients during COVID pandemic
Presenter: Sherif Farouk El Zawawy
Session: Poster session 02
219P - UK survey measuring informational needs & QoL in women living with metastatic breast cancer (LIMBER)
Presenter: Valerie Jenkins
Session: Poster session 02
220P - Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
Presenter: Philippe Aftimos
Session: Poster session 02
221P - Early prediction of efficacy of endocrine therapy (ET) in metastatic breast cancer (MBC): Pilot study with [18F]fluoro-estradiol-17β (18F-FES) PET/CT
Presenter: Alessandra Gennari
Session: Poster session 02
223P - Gene expression profiles in endocrine-resistant breast cancer
Presenter: Caroline Schagerholm
Session: Poster session 02
224P - Efficacy and safety of tenalisib, a PI3K delta/gamma and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Results from a phase II study
Presenter: Tamta Makharadze
Session: Poster session 02